ClinicalTrials.gg
CompletedNCT01707394Updated Mar 22, 2021

Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

A Phase 1 interventional study of Apixaban in Thromboembolism, sponsored by Bristol-Myers Squibb. Completed at 27 sites in 5 countries. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2021-03-22.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
1 Day to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 78 studies in Thromboembolism with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. Thromboembolism · United States.

Enrollment
42nd of 53
49 · median 192
Started
2013
the only one that year
Phase 1
4 of 78
1 open now
Registered
37th of 78
by date
Lead sponsor
2 of 78
Bristol-Myers Squibb

Among the 78 studies in Thromboembolism with a site in United States, this one is the 42nd largest by enrollment of the 53 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 1, and was the 37th registered.

Thromboembolism

288 studies on the registry are indexed under Thromboembolism; 42 are open to participants now.

Browse Thromboembolism studies →

Open to participants now

8 of the 78 studies in Thromboembolism with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Thromboembolism studies recruiting now, 23 (72%) set no upper age limit and 4 (13%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 1 Day to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Thromboembolism with a site in United States, or all of them as a file.
02

Study summary

CV185118 is a single dose Apixaban PK/PD study in pediatric participants. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric participants at risk for thrombosis

03

Conditions studied

  • Thromboembolism

Browse trials for

04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Participants with any stable disease that are at risk for a venous or arterial thrombotic disorder
  • Neonates ≥ 34 weeks gestational or ≥ 37 weeks post conceptual age (corrected gestational age) to \<18 years of age

    • Gestational and post-conceptual age will only be taken into consideration for eligibility up to 6 months of age
    • Neonates: defined as newly born (within 4 weeks)
  • Participants with any functional CVAD (Central Venous Access Device) in the upper or lower venous system

Exclusion criteria

Exclusion Criteria:

  • Current or recent (within 3 months of study drug administration) gastrointestinal disease or gastrointestinal surgery that, in the opinion of the investigator and the BMS Medical Monitor, could impact the absorption of the study drug
  • Active bleeding or high risk of bleeding
  • Inability to tolerate oral medication or administration of oral medication via an enteral tube (nasogastric tube [NG tube] or gastronomy tube [G-tube])
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Group 1: Apixaban (low dose)

    Drug: Apixaban

  • Experimental
    Group 2A: Apixaban (low dose)

    Drug: Apixaban

  • Experimental
    Group 2B: Apixaban (low dose)

    Drug: Apixaban

  • Experimental
    Group 3: Apixaban (low dose)

    Drug: Apixaban

  • Experimental
    Group 4: Apixaban (low dose)

    Drug: Apixaban

  • Experimental
    Group 5: Apixaban (low dose)

    Drug: Apixaban

  • Experimental
    Group 2A (higher dose): Apixaban (low dose)

    Drug: Apixaban

Interventions

  • Specified dose on specified days

    Also known as: BMS-562247

06

What researchers measure

Primary outcomes

  1. Estimated area under the plasma concentration-time curve [AUC(INF)] of Apixaban

    Time frame: Up to 26 hours, post dose (from Day 1 to Day 2)

  2. Maximum estimated plasma concentration (Cmax) of Apixaban

    Time frame: Up to 26 hours, post dose (from Day 1 to Day 2)

  3. Estimated time at which maximum plasma concentration occurs (Tmax) of Apixaban

    Time frame: Up to 26 hours, post dose (from Day 1 to Day 2)

Secondary outcomes

  1. Number of participants with Adverse Events (AEs)

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  2. Number of participants with Serious Adverse Events (SAEs)

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  3. Change from baseline in Vital Signs of body temperature

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  4. Change from baseline in Vital Signs of respiratory rate

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  5. Change from baseline in Vital Signs of blood pressure

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  6. Change from baseline in Vital Signs of heart rate

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  7. Number of participants with abnormalities in Physical Examinations

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  8. Change from baseline in Clinical Laboratory Tests of blood

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  9. Change from baseline in Clinical Laboratory Tests of blood serum

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  10. Change from baseline in Activated partial thromboplastin time (aPTT) clotting activity during treatment

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  11. Change from baseline in International Normalized Ratio (INR) clotting activity during treatment

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  12. Change from baseline in Prothrombin Time (PT) clotting activity during treatment

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  13. Change from baseline in Clinical Laboratory Tests of urine

    Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing

    Time frame: Up to 30 Days after last dosing

  14. Pharmacodynamics will be analyzed using anti-Factor Xa activity

    Time frame: Up to 26 hours, post dose (from Day 1 to Day 2)

07

Study locations

27 sites
  • Arkansas Children'S Hospital
    Little Rock, Arkansas 72202-3591, United States
  • Children'S Hospital Of Orange County
    Orange, California 92868, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Childrens National Medical Center
    Washington, District of Columbia 20010, United States
  • Children's Healthcare Of Atlanta
    Atlanta, Georgia 30322, United States
  • Blank Childrens Hospital
    Des Moines, Iowa 50309, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Kosair Charities Pediatric Clinical Research Unit
    Louisville, Kentucky 40202, United States
  • Children'S Mercy Hospital And Clinics
    Kansas City, Missouri 64108, United States
  • Saint Peter'S University Hospital
    New Brunswick, New Jersey 08901, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • ProMedica Toledo Children's Hospital
    Toledo, Ohio 43606, United States
  • Penn State Hershey Children'S Hospital
    Hershey, Pennsylvania 17033, United States
  • Childrens Hospital Of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hopsital Of Pittsburgh Of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Children's Hospital Of Pittsburgh Of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Childrens Hospital Of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Local Institution
    Parkville, Victoria 3052, Australia
  • University of Alberta - Edmonton Clinic Health Academy
    Edmonton, Alberta T6G 1C9, Canada
  • Local Institution
    Hamilton, Ontario L8S 4K1, Canada
  • The Hospital For Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Local Institution
    Ramat Gan, 52621, Israel
  • Local Institution
    Mexico City, Distrito Federal 14080, Mexico
  • Local Institution
    Mexico, Distrito Federal 04530, Mexico
  • Local Institution
    Guadalajara, Jalisco 44260, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64460, Mexico
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in Jun 2020, 89 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2012
First posted
Oct 16, 2012
StartActual
Jan 10, 2013
Primary completionActual
Jun 30, 2020
CompletionActual
Jun 30, 2020
Last update
Mar 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01707394
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Oct 16, 2012
Start date
Jan 10, 2013
Primary completion
Jun 30, 2020
Completion
Jun 30, 2020
Last update
Mar 22, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion